The next generation inhalable therapy based on RNA
Harnessing the power of RNA in combination with dry powder technology
Precision RNAi Delivery
Revolutionizing Pulmonary Care through RNAi Delivery
RNA interference (RNAi) is a natural cellular process of gene silencing that regulates gene expression. Building on this principle, our lung delivery platform is a pioneering advancement in pulmonary therapeutics. It allows the precise delivery of RNAi molecules, including small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), and microRNAs (miRNAs), to the lungs, targeting and treating pathologically overexpressed genes. Our platform technology, uniquely designed to work independently of RNA sequences, can effectively target a diverse array of pulmonary diseases.
AI-powered
Lipid Nanoparticle Formulation
Customized RNAi Delivery: AI-Optimized LNPs for Each Disease
Recognizing the distinct requirements of each disease, we utilize AI-driven technology to precisely customize lipid nanoparticles (LNPs) for the delivery of RNA molecules, locally to the lung. This tailored approach ensures optimal design of LNPs to match individual disease profiles, significantly enhancing their targeted delivery and effectiveness.
Introducing
NEM Technology
Therapy with Sustainable and Efficient Nano-Embedding
By utilizing our nano-embedded-microparticle (NEM) technology, we embed lipid nanoparticles within inhalable microparticles. This cutting-edge process yields a product that is remarkably stable at room temperature and tailored for large-scale production. Designed with both accessibility and sustainability in mind, our technology significantly reduces costs and energy consumption.
The Power of Dry Powder Inhalation
Revolutionizing Pulmonary Care through RNAi Delivery
Dry powder inhalation enhances patient compliance through self-administration. It offers greater convenience and substantially faster administration than other methods. With its rapid and discreet application, this method allows patients to seamlessly administer their treatment in public or social contexts, making it a practical choice for everyday life.
>
RNA
encapsulation
>
product
recovery
cost
reduction
stable at
Our Mission
At RNhale, our mission is driven by a commitment to bring advanced healthcare solutions to the patients, guided by extensive research experience and a comprehensive grasp of the existing challenges in current clinical practices. Our team, comprised of dedicated scientists and innovators, has firsthand experience with the drawbacks and limitations of existing procedures, particularly in the treatment of pulmonary diseases. This insight has reinforced our dedication to develop more effective, patient-centered technologies. We aim to create innovative solutions that not only reach the clinic but also improve the standard of care, offering new hope and better outcomes for patients affected by lung diseases.